Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase 3 -studie av revaccination i påfølgende svangerskap med bivalent RSV -vaksine og varighet av beskyttelse av en enkelt dose

18. november 2026 oppdatert av: Pfizer

En fase 3 -studie for å undersøke sikkerhet, toleranse og immunogenisitet av revaccinering av gravide deltakere under påfølgende svangerskap og utholdenhet av immunitet av en enkelt dose av en bivalent respirasjonssyncytial virus (RSV) vaksine.

This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

This study will include pregnant participants and their unborn babies (Cohort 1 and Cohort 2) and non-pregnant participants (Cohort 3), as described below:

  • Cohort 1- Pregnant participants who had previously received RSVpreF as part of a Pfizer clinical trial and have antibody data available from that trial will get a second dose of RSVpreF.
  • Cohort 2- Pregnant participants who received the RSVpreF in a previous pregnancy, either through commercial means with Abrysvo® or as part of a Pfizer clinical trial, will be randomly chosen to get either one dose of the RSVpreF or one dose of a placebo. This applies to those who do not have antibody data available from the earlier trial.

For both groups of pregnant participants, the study will look at how safe and well-tolerated the vaccine is during pregnancy, as well as how the body responds to it.

Infants will be monitored for six months after birth to check safety and antibodies level.

• Cohort 3- Nonpregnant participants who received RSVpreF during a previous pregnancy as part of an earlier clinical trial will have blood samples taken to see how well their immune response has persisted over time. Participants will not receive any vaccine.

Studietype

Intervensjonell

Registrering (Antatt)

550

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Buenos Aires, Argentina, 1044
        • Rekruttering
        • Centro de investigación Clínica OSECAC - Sede Jonas Salk
      • Buenos Aires, Argentina, C1428BNF
        • Rekruttering
        • Equipo Ciencia
      • Salta, Argentina, 4400
        • Rekruttering
        • Hospital Público Materno Infantil
    • Buenos Aires
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ABP
        • Rekruttering
        • Fundación Respirar
      • Mar del Plata, Buenos Aires, Argentina, 7600
        • Rekruttering
        • Clinica Del Niño Y La Madre
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Rekruttering
        • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Rekruttering
        • Instituto de Maternidad y Ginecología Nuestra Señora de las Mercedes
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • University of Alabama at Birmingham - School of Medicine
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • Children's of Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • Center for Research in Women's Health
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • University of Alabama at Birmingham Women & Infants Center
      • Mobile, Alabama, Forente stater, 36604
        • Rekruttering
        • USA Health Strada Patient Care Center
      • Mobile, Alabama, Forente stater, 36604
        • Rekruttering
        • USA Health Children's and Women's Hospital
    • Arizona
      • Phoenix, Arizona, Forente stater, 85008
        • Rekruttering
        • Valleywise Health Medical Center
      • Phoenix, Arizona, Forente stater, 85004
        • Rekruttering
        • ClinMed, LLC
      • Phoenix, Arizona, Forente stater, 85008
        • Rekruttering
        • Valleywise Comprehensive Health Center Women's Clinic
    • California
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • UCLA
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • Ronald Reagan UCLA Medical Center
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • UCLA (outpatient clinic)
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • Ronald Reagan UCLA Medical Center (inpatient hospital)
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • UCLA Clinical and Translational Research Center (research clinic)
      • Palo Alto, California, Forente stater, 94304
        • Rekruttering
        • Stanford University
      • Palo Alto, California, Forente stater, 94304
        • Rekruttering
        • Stanford University Medical Center
      • Palo Alto, California, Forente stater, 94304
        • Rekruttering
        • Lucile Packard Children's Hospital-Labor and Delivery Unit
      • Palo Alto, California, Forente stater, 94304
        • Rekruttering
        • Stanford Obstetrics Clinic
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Children's Hospital Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Anschutz Health Sciences Building (AHSB)
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • CU Research Pharmacy
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • University of Colorado AO1 UCH
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • University of Colorado Hospital Inpatient Pavilion
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • University of Colorado Hospital Outpatient Pavilion
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • University of Colorado Research II Building
    • Florida
      • North Miami Beach, Florida, Forente stater, 33162
        • Rekruttering
        • Citadelle Clinical Research
      • Panama City, Florida, Forente stater, 32405
        • Rekruttering
        • Emerald Coast OBGYN Clinical Research
      • Panama City, Florida, Forente stater, 32405
        • Rekruttering
        • Emerald Coast Pediatrics
      • Panama City, Florida, Forente stater, 32405
        • Rekruttering
        • HCA Florida Gulf Coast Hospital
    • Idaho
      • Boise, Idaho, Forente stater, 83706
        • Rekruttering
        • Saint Alphonsus Regional Medical Center
      • Boise, Idaho, Forente stater, 83712
        • Rekruttering
        • St. Luke's Boise Medical Center
      • Boise, Idaho, Forente stater, 83702
        • Rekruttering
        • Advanced Specialty Research
      • Idaho Falls, Idaho, Forente stater, 83404
        • Rekruttering
        • Clinical Research Prime
      • Nampa, Idaho, Forente stater, 83687
        • Rekruttering
        • Saint Alphonsus Medical Center
      • Nampa, Idaho, Forente stater, 83687
        • Rekruttering
        • St. Luke's Nampa Medical Center
    • Iowa
      • Ames, Iowa, Forente stater, 50010
        • Rekruttering
        • Mary Greeley Medical Center
      • Ames, Iowa, Forente stater, 50010
        • Rekruttering
        • McFarland Clinic, PC
      • Ames, Iowa, Forente stater, 50010
        • Rekruttering
        • Accellacare - McFarland
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • University of Kansas Medical Center
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • The University of Kansas Hospital
      • Kansas City, Kansas, Forente stater, 66103
        • Rekruttering
        • The University of Kansas Hospital Investigational Drug Services
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • The University of Kansas Medical Center Medical Office Building
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70119
        • Rekruttering
        • Velocity Clinical Research - New Orleans
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02118
        • Rekruttering
        • Boston Medical Center
    • Montana
      • Great Falls, Montana, Forente stater, 59405
        • Rekruttering
        • Boeson Research GTF
      • Great Falls, Montana, Forente stater, 59405
        • Rekruttering
        • OBGYN Associates
      • Kalispell, Montana, Forente stater, 59901
        • Rekruttering
        • Heart & Hands Midwifery
      • Missoula, Montana, Forente stater, 59804
        • Rekruttering
        • Boeson Research MSO
      • Missoula, Montana, Forente stater, 59804
        • Rekruttering
        • Origin Health
      • Missoula, Montana, Forente stater, 59804
        • Rekruttering
        • Boeson Research Laboratory
    • Nebraska
      • Grand Island, Nebraska, Forente stater, 68803
        • Rekruttering
        • Velocity Clinical Research, Grand Island
      • Norfolk, Nebraska, Forente stater, 68701
        • Rekruttering
        • Velocity Clinical Research, Norfolk
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87109
        • Rekruttering
        • Lovelace Women's Hospital
      • Albuquerque, New Mexico, Forente stater, 87107
        • Rekruttering
        • Velocity Clinical Research, Albuquerque
      • Albuquerque, New Mexico, Forente stater, 87107
        • Rekruttering
        • Presbyterian Hospital
      • Albuquerque, New Mexico, Forente stater, 87107
        • Rekruttering
        • UNM Hospital
    • New York
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Weill Cornell Medicine-Cornell University/New York Presbyterian Hospital-Alexandra Cohen Hospital for Women and Newborns
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University - Main Hospital and Clinics
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke University - Main Hospital and Clinics
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • Rekruttering
        • Cincinnati Children's Hospital Medical Center
    • South Carolina
      • Greenville, South Carolina, Forente stater, 29605
        • Rekruttering
        • Prisma Health Maternal Fetal Medicine
      • Greenville, South Carolina, Forente stater, 29605
        • Rekruttering
        • Prisma Health OBGYN Center
    • Texas
      • Houston, Texas, Forente stater, 77024
        • Rekruttering
        • Memorial Hermann Memorial City Hospital
      • Houston, Texas, Forente stater, 77204
        • Rekruttering
        • The University of Texas Health Science Center at Houston
      • Weatherford, Texas, Forente stater, 76086
        • Rekruttering
        • Medical City Weatherford
      • Weatherford, Texas, Forente stater, 76086
        • Rekruttering
        • Helios Clinical Research - WEA
      • Weatherford, Texas, Forente stater, 76086
        • Rekruttering
        • Weatherford OB/GYN Associates
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • Rekruttering
        • University of Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • University of Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • Rekruttering
        • University of Utah Clinical Neuroscience Center
      • Salt Lake City, Utah, Forente stater, 84108
        • Rekruttering
        • University of Utah Obstetrics and Gynecology Research Offices
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • University of Utah Madsen Health Center - Women's Health
    • Virginia
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Sentara Leigh Hospital
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • The Group For Women - Kempsville Office
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Tidewater Physicians for Women
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • WomensCare Center
      • Richmond, Virginia, Forente stater, 23226
        • Rekruttering
        • Clinical Research Partners, LLC
      • Richmond, Virginia, Forente stater, 23226
        • Rekruttering
        • Infusion Solutions, LLC
    • Washington
      • Seattle, Washington, Forente stater, 98105
        • Rekruttering
        • Seattle Children's Hospital
      • Seattle, Washington, Forente stater, 98195
        • Rekruttering
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, Forente stater, 98101
        • Rekruttering
        • Seattle Children's Research Institute
      • Seattle, Washington, Forente stater, 98133
        • Rekruttering
        • University of Washington - Northwest
    • Fajara
      • Banjul, Fajara, Gambia, PO Box 273
        • Rekruttering
        • Medical Research Council Unit
    • Free State
      • Bloemfontein, Free State, Sør-Afrika, 9301
        • Rekruttering
        • Josha Research
    • Gauteng
      • Johannesburg, Gauteng, Sør-Afrika, 2001
        • Rekruttering
        • Wits RHI
      • Johannesburg, Gauteng, Sør-Afrika, 1864
        • Rekruttering
        • University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA)
      • Pretoria, Gauteng, Sør-Afrika, 0181
        • Rekruttering
        • Into Research
      • Pretoria, Gauteng, Sør-Afrika, 0152
        • Rekruttering
        • Setshaba Research Centre
    • Western Cape
      • Cape Town, Western Cape, Sør-Afrika, 7700
        • Rekruttering
        • MRC Unit on Child And Adolescent Health
      • Cape Town, Western Cape, Sør-Afrika, 7500
        • Rekruttering
        • Family Clinical Research Unit (Fam-Cru)
      • Cape Town, Western Cape, Sør-Afrika, 7700
        • Rekruttering
        • University of Cape Town Lung Institute (Pty) Ltd

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 sekund og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Pregnant Participants-Cohort 1 and Cohort 2 Key Inclusion Criteria

  • Women aged 18 to 49 who are pregnant, between 24 and 36 weeks along, and expecting one baby without known risks for complications can participate.
  • Had the RSVpreF or Abrysvo vaccine during a previous pregnancy.
  • Had an ultrasound scan at 18 weeks or later during their current pregnancy, with no major fetal problems detected.
  • Based on their medical history, physical check-up, and the doctor's judgment, they are found suitable to join the study.
  • Agrees to let their baby take part in the study and gives their permission.
  • Able to sign a consent form, agreeing to follow the rules and conditions of the study.

Key Exclusion Criteria

  • Received any approved or experimental RSV vaccine since their previous pregnancy.
  • Has a pre-pregnancy body mass index (BMI) over 40 kg/m2.
  • History of a severe bad reaction to a vaccine or a serious allergic reaction (like anaphylaxis) to any ingredient in the study vaccine or a similar vaccine.
  • Current pregnancy problems or issues at the time of giving consent.
  • Previous pregnancy issues or problems at the time of giving consent.
  • Women who are breastfeeding at the time of enrollment

Infant Participants

  • Proof that the parent(s) or legal guardian(s) has signed and dated a consent form.
  • Parent(s) or legal guardian(s) must agree to attend scheduled visits and follow the study plan, including laboratory tests and other procedures.

Nonpregnant Participants-Cohort 3 Key Inclusion Criteria

  • Have already received one dose of the RSVpreF vaccine during their previous pregnancy as part of the Pfizer clinical trial, and the results from that time can be used for this study.
  • Able to sign a consent form, agreeing to follow the rules and requirements of the study.

Key Exclusion Criteria

  • Received any approved or experimental RSV vaccine after participating in the Pfizer clinical trial.
  • Taking part in other studies with new drugs within 28 days before giving consent or during the study period.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Single Dose

Eksperimentell: RSVpreF

Single Dose

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prosentandel av gravide deltakere som rapporterer bivirkninger
Tidsramme: Fra dag 1 til 4 uker etter vaksinasjon
Fra dag 1 til 4 uker etter vaksinasjon
Prosentandel av gravide deltakere som rapporterer om alvorlige bivirkninger
Tidsramme: Fra dag 1 gjennom hele studien
Fra dag 1 gjennom hele studien
Hos spedbarnsdeltakere født av gravide deltakere som mottar en annen dose av studieinngrepet, er prosentandelen av deltakerne som rapporterer bivirkninger.
Tidsramme: Fra fødsel til 1 måned
Fra fødsel til 1 måned
Hos spedbarnsdeltakere født av gravide deltakere som mottar en annen dose av studieinngrep, er prosentandelen av deltakerne som rapporterer om alvorlige bivirkninger og nylig diagnostiserte medisinske tilstander.
Tidsramme: Fra fødselen til 6 måneders alder.
Fra fødselen til 6 måneders alder.
Andel deltakere som oppnår nøytraliserende antistoff mot RSV A og RSV B ved fødselen
Tidsramme: Ved fødselen
Ved fødselen
Percentage of pregnant participants reporting local reactions
Tidsramme: From Day 1 Through at least Day 7 after Vaccination

Pain at the injection site, redness, and swelling

From Day 1 Through at least Day 7 after Vaccination
Percentage of pregnant participants reporting systemic events
Tidsramme: From Day 1 Through at least Day 7 after Vaccination

Fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain, and joint pain

From Day 1 Through at least Day 7 after Vaccination

Sekundære resultatmål

Resultatmål
Tidsramme
Andel deltakere som oppnår nøytraliserende antistoff mot RSV A og RSV B etter 3 måneder og 6 måneder
Tidsramme: Etter 3 måneder og 6 måneder
Etter 3 måneder og 6 måneder

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. april 2025

Primær fullføring (Antatt)

24. februar 2028

Studiet fullført (Antatt)

24. februar 2028

Datoer for studieregistrering

Først innsendt

4. mars 2025

Først innsendt som oppfylte QC-kriteriene

4. mars 2025

Først lagt ut (Faktiske)

10. mars 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • C3671059
  • C3671059-OPENLABEL; Marguerite (Annen identifikator: Alias Study Number)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere